Effects of cyclooxygenase‑2 gene silencing on the biological behavior of SKOV3 ovarian cancer cells Retraction in /10.3892/mmr.2021.12346

Guo,Feng‑Jun; Tian,Jing‑Yan; Jin,Yue‑Mei; Wang,Ling; Yang,Rui‑Qi; Cui,Man‑Hua

doi:10.3892/mmr.2014.2732

Effects of cyclooxygenase‑2 gene silencing on the biological behavior of SKOV3 ovarian cancer cells

Retraction in: /10.3892/mmr.2021.12346

Authors:
- Feng‑Jun Guo
- Jing‑Yan Tian
- Yue‑Mei Jin
- Ling Wang
- Rui‑Qi Yang
- Man‑Hua Cui
View Affiliations

Affiliations: Department of Obstetrics and Gynaecology, The Second Hospital, Jilin University, Changchun 130041, P.R. China, Department of Urology, Second Division of the First Hospital, Jilin University, Changchun 130021, P.R. China
Published online on: October 21, 2014 https://doi.org/10.3892/mmr.2014.2732
Pages: 59-66
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effects of plasmid-mediated RNA interference targeting of cyclooxygenase‑2 (COX‑2) on the biological behaviors of SKOV3 human ovarian cancer cells and to analyze the function of COX‑2 in carcinogenesis and development of ovarian cancer. A COX‑2 small hairpin (sh)RNA sequence was designed and synthesized and pGPU6‑COX‑2‑shRNA plasmids were constructed. The recombinant vector plasmids were stably transfected into SKOV3 cells. The mRNA and protein expression of COX‑2 was subsequently analyzed by quantitative polymerase chain reaction and western blot analysis, respectively. MTT and colony formation assays were used to detect the cellular proliferation ability and flow cytometry was performed to detect phase changes in the cell cycle. Finally, a Transwell assay was used to detect cell invasion. The SKOV3 cells, transfected with recombinant vector plasmids, and control cells, were injected into nude mice and the tumor emergence time, volume and weight were measured. The impact of COX‑2 gene silencing on the growth of xenograft tumors in nude mice was analyzed. Following transfection of the pGPU6‑COX‑2‑shRNA plasmid, in vitro analyses indicated that the shRNA efficiently suppressed the mRNA and protein expression of COX‑2. COX‑2 gene silencing significantly inhibited the proliferation and invasion ability of SKOV3 cells, leading to cell cycle arrest in G1. The tumor formation time in the interference group was significantly prolonged, and the tumor volume and weight were significantly decreased, as compared with the control group. Plasmid‑mediated shRNA was shown to effectively silence COX‑2 expression in SKOV3 ovarian cancer cells. It was identified that COX‑2 functioned in regulating proliferation, cell cycle and invasion of ovarian cancer cells. These findings provided a theoretical basis for determining the function of COX‑2 in the development of ovarian cancer and suggested that COX‑2 may be an effective target for gene therapy and clinical applications.

View Figures

View References

1	Deraco M, Baratti D, Laterza B, et al: Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer. Eur J Surg Oncol. 37:4–9. 2011. View Article : Google Scholar
2	Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D and Redondo A: Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol. 118:88–92. 2010.PubMed/NCBI
3	Ji B, Liu Y, Zhang P, et al: COX-2 expression and tumor angiogenesis in thyroid carcinoma patients among northeast Chinese population-result of a single-center study. Int J Med Sci. 9:237–242. 2012. View Article : Google Scholar
4	Holmes MD, Chen WY, Schnitt SJ, et al: COX-2 expression predicts worse breast cancer prognosis and does not modify the association with aspirin. Breast Cancer Res Treat. 130:657–662. 2011. View Article : Google Scholar : PubMed/NCBI
5	Yao L, Liu F, Hong L, et al: The function and mechanism of COX-2 in angiogenesis of gastric cancer cells. J Exp Clin Cancer Res. 30:132011. View Article : Google Scholar : PubMed/NCBI
6	Kwagyan J, Apprey V and Ashktorab H: Linkage disequilibrium and haplotype analysis of COX-2 and risk of colorectal adenoma development. Clin Transl Sci. 5:60–64. 2012. View Article : Google Scholar : PubMed/NCBI
7	Chen YF, Luo RZ, Li Y, et al: High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 270:1009–1017. 2013. View Article : Google Scholar : PubMed/NCBI
8	Thill M, Fischer D, Kelling K, et al: Expression of vitamin D receptor (VDR), cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in benign and malignant ovarian tissue and 25-hydroxycholecalciferol (25(OH2)D3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J Steroid Biochem Mol Biol. 121:387–390. 2010.
9	Raspollini MR, Amunni G, Villanucci A, et al: COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer. Acta Obstet Gynecol Scand. 85:493–498. 2006. View Article : Google Scholar : PubMed/NCBI
10	Lee JY, Myung SK and Song YS: Prognostic role of cyclooxygenase-2 in epithelial ovarian cancer: a meta-analysis of observational studies. Gynecol Oncol. 129(3): 613–619. 2013. View Article : Google Scholar : PubMed/NCBI
11	Raspollini MR, Amunni G, Villanucci A, et al: Increased cyclooxygenase-2 (COX-2) and P-glycoprotein-170 (MDR1) expression is associated with chemotherapy resistance and poor prognosis. Analysis in ovarian carcinoma patients with low and high survival. Int J Gynecol Cancer. 15:255–260. 2005. View Article : Google Scholar
12	Wang L, Chen W and Yang J: Effects of cyclooxygenase-2 siRNA-mediated gene silencing on proliferation and apoptosis of human colon cancer cells. Suzhou Univ J Med Sci. 2:16–19. 2008.(In Chinese).
13	Juncker-Jensen A, Deryugina EI, Rimann I, et al: Tumor MMP-1 activates endothelial PAR1 to facilitate vascular intravasation and metastatic dissemination. Cancer Res. 73:4196–4211. 2013. View Article : Google Scholar : PubMed/NCBI
14	Lee JS, Choi YD, Lee JH, et al: Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression. Int J Gynecol Cancer. 16(Suppl 1): 247–253. 2006. View Article : Google Scholar : PubMed/NCBI
15	Stetler-Stevenson WG and Yu AE: Proteases in invasion: matrix metalloproteinases. Semin Cancer Biol. 11:143–152. 2001. View Article : Google Scholar : PubMed/NCBI
16	Nguyen DX, Bos PD and Massaué J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
18	Xu X, Shen A and Wang Zh: Expressions and significances of COX-2, VEGF, MMP-9 in epithelial ovarian carcinoma tissues. Basic Clin Onco. 23:67–469, (In Chinese).
19	Symowicz J, Adley BP, Woo MM, et al: Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res. 65:2234–2242. 2005. View Article : Google Scholar : PubMed/NCBI
20	Leung E, McArthur D, Morris A, et al: Cyclooxygenase-2 inhibition prevents migration of colorectal cancer cells to extracellular matrix by down-regulation of matrix metalloproteinase-2 expression. Dis Colon Rectum. 51:342–347. 2008. View Article : Google Scholar : PubMed/NCBI
21	Pan MR, Chuang LY and Hung WC: Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett. 508:365–368. 2001. View Article : Google Scholar : PubMed/NCBI
22	Li T, Lu J and Zhong Y: Lentivirus-mediated shRNA interference targeting cyclooxygenase-2 inhibits growth of human non-small cell lung cancer. J BUON. 18:908–14. 2013.PubMed/NCBI
23	Liu Z, Wu XZ, Song R, et al: RNAi-mediated knockdown of cyclooxygenase 2 inhibits the growth and migration of SaOS2 human osteosarcoma cells. Zhonghua Yi Xue Za Zhi. 93:1028–31. 2013.(In Chinese).
24	Zhang L, Wu YD, Li P, et al: Effects of cyclooxygenase-2 on human esophageal squamous cell carcinoma. World J Gastroenterol. 17:4572–80. 2011. View Article : Google Scholar : PubMed/NCBI